Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-304 in Advanced HER2-Expressing Solid Tumors
NCT07334119Phase 1Recruiting
- Sponsor
- Myeloid Therapeutics
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MT-304 in Solid tumors (2 arms), sponsored by Myeloid Therapeutics. Primary endpoints: Type, incidence and severity of Adverse Events, Number of Participants With Change From Baseline in Vital Signs and 4 more. Started Nov 2025; status: recruiting.
02
Drugs
MT-304
03
Conditions
Solid tumors
Beyond the preview
Go deeper on NCT07334119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334119.